US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neumora Therapeutics, Inc.

1.02

+0.209925.91%

Post-market: 1.040.0200+1.96%19:59 EDT

Volume:1.84M

Turnover:1.78M

Market Cap:164.98M

PE:-0.63

High:1.05

Open:0.8400

Low:0.8125

Close:0.8101

Loading ...

Overview Company News Filings

Neumora Therapeutics Inc Conducted Annual Stockholders Meeting

Neumora Therapeutics Faces Nasdaq Non-Compliance Notice

BRIEF-Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance Notice

Neumora Therapeutics Inc -on May14, Receives Nasdaq Non-Compliance Notice - SEC Filing

THOMSON REUTERS

Neumora Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement

Neumora Therapeutics’ Earnings Call: Progress Amid Challenges

Neumora Therapeutics Reports Q1 2025 Financial Results

Neumora Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Neumora Therapeutics Inc - Q1 EPS $-0.42

THOMSON REUTERS

Neumora Therapeutics Reports Increased Net Loss of $68M in Q1 2025, Up from $53.7M in 2024

Neumora Therapeutics Q1 EPS $(0.42) Misses $(0.38) Estimate

Press Release: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Calendar of U.S. Earnings Expected in the Week Ahead

Neumora Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), ImmunityBio (IBRX) and Exelixis (EXEL)

Galapagos CEO Paul Stoffels to Retire; Henry Gosebruch Named SpinCo Chief

MT Newswires Live

Galapagos Announces Executive Leadership Updates

Neumora Therapeutics Cut to Underperform From Buy by B of A Securities

Neumora Therapeutics Inc : Bofa Global Research Cuts to Underperform From Buy; Cuts Price Objective to $1 From $7

THOMSON REUTERS

Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NMRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":1.02,"timestamp":1749240000000,"preClose":0.8101,"halted":0,"volume":1844241,"hourTrading":{"tag":"盘后","latestPrice":1.04,"preClose":1.02,"latestTime":"19:59 EDT","volume":51617,"amount":53983.9776,"timestamp":1749254390750},"delay":0,"floatShares":85291959,"shares":161747922,"eps":-1.610306,"marketStatus":"Market Closed","change":0.2099,"latestTime":"06-06 16:00:00 EDT","open":0.84,"high":1.05,"low":0.8125,"amount":1777324.06161093,"amplitude":0.293174,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.610306,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":0.8101,"preHourTrading":{"tag":"盘前","latestPrice":0.8499,"preClose":0.8101,"latestTime":"09:09 EDT","volume":1377,"amount":1180.41318711,"timestamp":1749215389167},"postHourTrading":{"tag":"盘后","latestPrice":1.04,"preClose":1.02,"latestTime":"19:59 EDT","volume":51617,"amount":53983.9776,"timestamp":1749254390750},"volumeRatio":3.2314260632258276,"impliedVol":1.8788,"impliedVolPercentile":0.664},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","floatShares":85291959,"roa":"-48.50%","roe":"-79.05%","lyrEps":-1.529624,"volumeRatio":3.2314260632258276,"shares":161747922,"dividePrice":0,"high":1.05,"amplitude":0.293174,"preClose":0.8101,"low":0.8125,"week52Low":0.611,"pbRate":"0.72","week52High":17.1874,"institutionHeld":0,"latestPrice":1.02,"eps":-1.610306,"divideRate":0,"volume":1844241,"delay":0,"ttmEps":-1.610306,"open":0.84,"prevYearClose":10.6,"prevWeekClose":0.7163,"prevMonthClose":0.7163,"prevQuarterClose":1,"fiveDayClose":0.7163,"twentyDayClose":0.6386,"sixtyDayClose":1.38},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NMRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539693203","title":"Neumora Therapeutics Inc Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539693203","media":"Reuters","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539693203?lang=en_us&edition=fundamental","pubTime":"2025-05-31 05:21","pubTimestamp":1748640099,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc held its Annual Meeting of Stockholders on May 28, 2025. Stockholders elected Alaa Halawa and Maykin Ho, Ph.D., as Class II directors. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The repricing of certain outstanding stock options under the company's equity incentive plans was approved. Amendments to the company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio ranging from 1-for-5 to 1-for-30 were also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the El","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL171TrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2536232383","title":"Neumora Therapeutics Faces Nasdaq Non-Compliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2536232383","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536232383?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:54","pubTimestamp":1747428849,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. ( ($NMRA) ) has shared an update. On May 14, 2025, Neumora Therapeutics, Inc. received a notice from Nasdaq indicating n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-faces-nasdaq-non-compliance-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-faces-nasdaq-non-compliance-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIW.SI","TSYW.SI","USJW.SI","IE00BGHQF748.EUR","QID","LU2095319765.USD","SQQQ","BK4588","LENZ","QLD","TQQQ","MNQmain","IE00BKPKM429.USD","BK4139","BK4112","BK4585","LU2210150020.SGD","USAW.SI","NMRA","BK4539","IE00B64PRP62.GBP","NQmain","IE00B3QW5Z07.USD","NDAQ",".IXIC","PSQ","BK4007","LU2210149790.SGD"],"gpt_icon":0},{"id":"2536323883","title":"BRIEF-Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2536323883","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536323883?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:43","pubTimestamp":1747428202,"startTime":"0","endTime":"0","summary":"BRIEF-Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance NoticeMay 16 (Reuters) - Neumora Therapeutics Inc NMRA.O:NEUMORA THERAPEUTICS INC -ON MAY14, RECEIVES NASDAQ NON-COMPLIANCE NOTICE - SEC FILINGFurther company coverage: NMRA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nFWN3RO1AA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2536786328","title":"Neumora Therapeutics Inc -on May14, Receives Nasdaq Non-Compliance Notice - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2536786328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536786328?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:40","pubTimestamp":1747428034,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nFWN3RO1AA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2536328556","title":"Neumora Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2536328556","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536328556?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:27","pubTimestamp":1747427245,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc. has announced a regulatory issue concerning its Nasdaq listing. On May 14, 2025, the company received a notice from The Nasdaq Stock Market LLC indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5450. Neumora has 180 days, until November 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. Failure to meet this requirement could lead to potential delisting, although the company may apply for additional time by transferring to The Nasdaq Capital Market. Neumora is considering options to address the issue, including a reverse stock split, which requires stockholder approval.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL968M94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2535382570","title":"Neumora Therapeutics’ Earnings Call: Progress Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2535382570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535382570?lang=en_us&edition=fundamental","pubTime":"2025-05-16 10:18","pubTimestamp":1747361904,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. (($NMRA)) has held its Q1 earnings call. Read on for the main highlights of the call. Neumora Therapeutics’ recent earni...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-earnings-call-progress-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-earnings-call-progress-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","NMRA","LENZ"],"gpt_icon":0},{"id":"2535276926","title":"Neumora Therapeutics Reports Q1 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535276926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535276926?lang=en_us&edition=fundamental","pubTime":"2025-05-13 12:21","pubTimestamp":1747110083,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. ( ($NMRA) ) has released its Q1 earnings. Here is a breakdown of the information Neumora Therapeutics, Inc. presented to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neumora-therapeutics-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","NMRA","LENZ","BK4539"],"gpt_icon":0},{"id":"2535787370","title":"Neumora Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535787370","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535787370?lang=en_us&edition=fundamental","pubTime":"2025-05-13 05:01","pubTimestamp":1747083715,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryNeumora Therapeutics Inc NMRA.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nL8N3RK2RM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"gpt_icon":0},{"id":"2535781543","title":"Neumora Therapeutics Inc - Q1 EPS $-0.42","url":"https://stock-news.laohu8.com/highlight/detail?id=2535781543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535781543?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:13","pubTimestamp":1747080808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nFWN3RK2EN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2535789488","title":"Neumora Therapeutics Reports Increased Net Loss of $68M in Q1 2025, Up from $53.7M in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2535789488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535789488?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:06","pubTimestamp":1747080380,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter ending March 31, 2025. The company reported a net loss of $68.0 million, compared to a net loss of $53.7 million for the same period in 2024. As of March 31, 2025, Neumora's cash, cash equivalents, and marketable securities totaled $249.4 million. The company expects its current cash position, combined with a $20 million draw from a $125 million venture debt facility secured from K2 HealthVentures, to support operations into 2027. In terms of business operations, Neumora continues to advance its pipeline of therapeutics for brain diseases. The company is progressing with the Phase 1b signal-seeking study of NMRA-511 in Alzheimer's disease agitation and has resumed enrollment for the KOASTAL-3 and -2 studies for major depressive disorder, with topline data expected in 2026. Additionally, Neumora plans to advance its M4 positive allosteric modulator  program into t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDL6B22K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2535507789","title":"Neumora Therapeutics Q1 EPS $(0.42) Misses $(0.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535507789","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535507789?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:02","pubTimestamp":1747080123,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 23.53 percent decrease over losses of $(0.34) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45359018/neumora-therapeutics-q1-eps-0-42-misses-0-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","LENZ"],"gpt_icon":0},{"id":"2535789555","title":"Press Release: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535789555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535789555?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:01","pubTimestamp":1747080060,"startTime":"0","endTime":"0","summary":"On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025. Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026. WATERTOWN, Mass., May 12, 2025  -- Neumora Therapeutics, Inc.  a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.NMRA-511: On Track to Report Data from Phase 1b Study in Alzheimer's Disease  Agitation Around the End of 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NMRA","BK4007","BK4139","BK4081","BK4563","LENZ","PAM"],"gpt_icon":0},{"id":"2534666246","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2534666246","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534666246?lang=en_us&edition=fundamental","pubTime":"2025-05-12 18:00","pubTimestamp":1747044000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KSPI","ENTA","URGN","TASK","AVIR","NMRA","SPG","TNGX","KBDC","FTRE","VINP","AMPY","PNNT","OGI","IAS","CLLS","DVA","SGRY","EVEX","FOX","INR","SKYX","SWX","CTRI","CHRS","HBM","BRDG","XENE","PLUG","VFF","EDIT","FOXA","AUPH","AGEN","LAND","WTRG","SMR","SBH","METC","ACHR","MNDY","PANL","GTM","GPRO","BALY","ARCT","LINC","HPK","ZI","LFT","AQST"],"gpt_icon":0},{"id":"2534189463","title":"Neumora Therapeutics Inc  expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534189463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534189463?lang=en_us&edition=fundamental","pubTime":"2025-05-10 04:48","pubTimestamp":1746823685,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc  expected to post a loss of37cents a share - Earnings Preview Neumora Therapeutics Inc NMRA.OQ NMRA.O is expected to show no change in quarterly revenue when it reports  resul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH3B9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"gpt_icon":0},{"id":"2531046231","title":"Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), ImmunityBio (IBRX) and Exelixis (EXEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531046231","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531046231?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:50","pubTimestamp":1745855457,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA – Research Report),...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neumora-therapeutics-inc-nmra-immunitybio-ibrx-and-exelixis-exel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neumora-therapeutics-inc-nmra-immunitybio-ibrx-and-exelixis-exel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IBRX","BK4139","EXEL","NMRA","BK4532","HCSG","BK4137"],"gpt_icon":0},{"id":"2529235599","title":"Galapagos CEO Paul Stoffels to Retire; Henry Gosebruch Named SpinCo Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2529235599","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529235599?lang=en_us&edition=fundamental","pubTime":"2025-04-22 05:04","pubTimestamp":1745269497,"startTime":"0","endTime":"0","summary":"Galapagos  said Monday that CEO Paul Stoffels plans to retire upon the appointment of a successor within the next 12 months.The board appointed Henry Gosebruch as CEO of its XYZ SpinCo unit, which will separate from the company and be funded with about 2.45 billion euros  in cash and cash equivalents, Galapagos said.Gosebruch most recently served as CEO of Neumora , according to the company.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLPG","BK4007","NMRA","BK4139"],"gpt_icon":0},{"id":"2529302053","title":"Galapagos Announces Executive Leadership Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2529302053","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529302053?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:10","pubTimestamp":1745266200,"startTime":"0","endTime":"0","summary":"Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo. Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV , a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements.Dr. Stoffels1, CEO and Chair of the Board of Directors at Galapagos, commented, “Henry’s appointment marks a key milestone as we progress on our planned Separation. His extensive biotech experience, leadership, and track record in creating shareholder value through M&A and business development will be of significant value to SpinCo, as it focuses on building a differentiated pipeline of innovative medicines with robust proof-of-concept.”Dr. Stoffels, Chair and CEO of Galapagos, has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of a successor, and to remain as No","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galapagos-announces-executive-leadership-updates-201000384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EU","IPO","STRK","BK4595","BK4600","BK4156","BK4588","BK4596","BK4585","BK4007","BK4139","NMRA","BK4516","BK4023","GLPG"],"gpt_icon":1},{"id":"2524498780","title":"Neumora Therapeutics Cut to Underperform From Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2524498780","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524498780?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:39","pubTimestamp":1743597540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NMRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 08:39 ET (12:39 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2524030466","title":"Neumora Therapeutics Inc : Bofa Global Research Cuts to Underperform From Buy; Cuts Price Objective to $1 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2524030466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524030466?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:07","pubTimestamp":1743592077,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2524145174","title":"Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524145174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524145174?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:05","pubTimestamp":1743584724,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazee...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-inc-faces-setbacks-with-delayed-mdd-program-and-discontinued-bipolar-depression-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-inc-faces-setbacks-with-delayed-mdd-program-and-discontinued-bipolar-depression-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NMRA","ABVC","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":116,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"NMRA","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.42},{"market":"US","date":"2024-11-12","symbol":"NMRA","fiscalQuarterEnding":"2024/09","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.375,"hold":0.625,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.625,"analysts":8,"updateTime":1743566400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NMRA","date":"2025-06-06","current":-0.507762,"percent":0.906173,"low":-19.620035,"twenty":-12.041995,"median":-6.685868,"eighty":-1.033834,"high":-0.385538,"avg":-7.390899,"sd":5.192566,"marketCap":131031991},"quantilePoints":[{"date":"2023-09-15","current":-19.620035,"twenty":-19.620035,"median":-19.620035,"eighty":-19.620035,"marketCap":2583134632},{"date":"2023-09-22","current":-12.753675,"twenty":-18.754446,"median":-15.453663,"eighty":-12.753675,"marketCap":1679123396},{"date":"2023-09-28","current":-13.691957,"twenty":-17.415667,"median":-13.628246,"eighty":-12.772209,"marketCap":1802655635},{"date":"2023-10-05","current":-13.813351,"twenty":-16.65135,"median":-13.723658,"eighty":-12.773914,"marketCap":1818638110},{"date":"2023-10-13","current":-11.180579,"twenty":-14.994038,"median":-13.691957,"eighty":-12.763183,"marketCap":1472012710},{"date":"2023-10-20","current":-11.493728,"twenty":-13.94093,"median":-13.080265,"eighty":-11.639864,"marketCap":1513241282},{"date":"2023-10-27","current":-14.254079,"twenty":-14.080107,"median":-13.080265,"eighty":-11.690896,"marketCap":1876663508},{"date":"2023-11-03","current":-10.734234,"twenty":-13.848145,"median":-12.776843,"eighty":-11.493728,"marketCap":1667466680},{"date":"2023-11-10","current":-10.420012,"twenty":-13.826354,"median":-12.7442,"eighty":-11.403032,"marketCap":1618655149},{"date":"2023-11-17","current":-11.79624,"twenty":-13.813351,"median":-12.154821,"eighty":-11.403032,"marketCap":1832439792},{"date":"2023-11-24","current":-11.717599,"twenty":-13.766958,"median":-11.806071,"eighty":-11.438475,"marketCap":1820223526},{"date":"2023-12-01","current":-12.041995,"twenty":-13.704638,"median":-11.815901,"eighty":-11.48267,"marketCap":1870615621},{"date":"2023-12-08","current":-12.26809,"twenty":-13.59002,"median":-11.825731,"eighty":-11.493283,"marketCap":1905737383},{"date":"2023-12-15","current":-14.381583,"twenty":-13.717318,"median":-11.894542,"eighty":-11.493728,"marketCap":2234049513},{"date":"2023-12-22","current":-13.75245,"twenty":-13.821153,"median":-12.041995,"eighty":-11.521564,"marketCap":2136319390},{"date":"2023-12-29","current":-16.848963,"twenty":-14.008036,"median":-12.137729,"eighty":-11.563317,"marketCap":2617334836},{"date":"2024-01-05","current":-16.111698,"twenty":-14.24211,"median":-12.26809,"eighty":-11.573312,"marketCap":2502807349},{"date":"2024-01-12","current":-14.991056,"twenty":-14.660761,"median":-12.728927,"eighty":-11.585874,"marketCap":2328725569},{"date":"2024-01-19","current":-14.411074,"twenty":-14.428768,"median":-12.751722,"eighty":-11.613398,"marketCap":2238630612},{"date":"2024-01-26","current":-14.843603,"twenty":-15.020547,"median":-12.776843,"eighty":-11.648787,"marketCap":2305820071},{"date":"2024-02-02","current":-14.991056,"twenty":-15.264335,"median":-13.370218,"eighty":-11.652719,"marketCap":2328725569},{"date":"2024-02-09","current":-17.1537,"twenty":-15.346909,"median":-13.691957,"eighty":-11.671529,"marketCap":2664672864},{"date":"2024-02-16","current":-18.490607,"twenty":-15.539581,"median":-13.783396,"eighty":-11.691031,"marketCap":2872349373},{"date":"2024-02-23","current":-18.500437,"twenty":-15.932789,"median":-13.819852,"eighty":-11.69454,"marketCap":2873876407},{"date":"2024-03-01","current":-17.330643,"twenty":-16.668088,"median":-13.939224,"eighty":-11.709735,"marketCap":2692159461},{"date":"2024-03-08","current":-12.297819,"twenty":-16.990518,"median":-13.97363,"eighty":-11.717599,"marketCap":2901363004},{"date":"2024-03-15","current":-10.189453,"twenty":-16.81554,"median":-13.826354,"eighty":-11.69454,"marketCap":2403946708},{"date":"2024-03-22","current":-9.414974,"twenty":-16.668088,"median":-13.783396,"eighty":-11.650753,"marketCap":2221227691},{"date":"2024-03-28","current":-8.492333,"twenty":-16.613039,"median":-13.722203,"eighty":-11.579976,"marketCap":2003553733},{"date":"2024-04-05","current":-9.246609,"twenty":-16.364935,"median":-13.534996,"eighty":-11.491504,"marketCap":2181506166},{"date":"2024-04-12","current":-9.435178,"twenty":-16.111698,"median":-12.865966,"eighty":-11.216259,"marketCap":2225994275},{"date":"2024-04-19","current":-7.105005,"twenty":-15.954415,"median":-12.753675,"eighty":-10.606446,"marketCap":1676248365},{"date":"2024-04-26","current":-6.123304,"twenty":-15.846283,"median":-12.728927,"eighty":-10.162515,"marketCap":1444640411},{"date":"2024-05-03","current":-6.231441,"twenty":-15.669339,"median":-12.297819,"eighty":-9.792112,"marketCap":1470152824},{"date":"2024-05-10","current":-6.135514,"twenty":-15.610358,"median":-12.155389,"eighty":-9.435178,"marketCap":1558549450},{"date":"2024-05-17","current":-6.047595,"twenty":-15.433415,"median":-12.120637,"eighty":-9.273547,"marketCap":1536216091},{"date":"2024-05-24","current":-5.846636,"twenty":-15.423584,"median":-11.91675,"eighty":-8.957021,"marketCap":1485168412},{"date":"2024-05-31","current":-6.085275,"twenty":-15.399992,"median":-11.884712,"eighty":-8.469435,"marketCap":1545787530},{"date":"2024-06-07","current":-6.235993,"twenty":-15.362637,"median":-11.806071,"eighty":-7.09423,"marketCap":1584073290},{"date":"2024-06-14","current":-6.248553,"twenty":-15.342977,"median":-11.75692,"eighty":-6.904314,"marketCap":1587263770},{"date":"2024-06-21","current":-5.557759,"twenty":-15.335113,"median":-11.717599,"eighty":-6.419582,"marketCap":1411787373},{"date":"2024-06-28","current":-5.777557,"twenty":-15.335113,"median":-11.707769,"eighty":-6.279953,"marketCap":1467620772},{"date":"2024-07-05","current":-6.129234,"twenty":-15.228947,"median":-11.690896,"eighty":-6.264891,"marketCap":1556954210},{"date":"2024-07-12","current":-7.253346,"twenty":-15.12278,"median":-11.653703,"eighty":-6.277441,"marketCap":1842502165},{"date":"2024-07-15","current":-6.939348,"twenty":-15.110984,"median":-11.648787,"eighty":-6.278697,"marketCap":1762740166},{"date":"2024-08-02","current":-7.931581,"twenty":-15.099188,"median":-11.648787,"eighty":-6.279953,"marketCap":2014788082},{"date":"2024-08-09","current":-6.56038,"twenty":-15.040207,"median":-11.579976,"eighty":-6.279953,"marketCap":1798711865},{"date":"2024-08-16","current":-6.881395,"twenty":-14.991056,"median":-11.493728,"eighty":-6.279953,"marketCap":1886727125},{"date":"2024-08-23","current":-6.712133,"twenty":-14.991056,"median":-11.447336,"eighty":-6.393648,"marketCap":1840319079},{"date":"2024-08-30","current":-6.54287,"twenty":-14.922244,"median":-11.299816,"eighty":-6.436952,"marketCap":1793911032},{"date":"2024-09-06","current":-6.297731,"twenty":-14.859331,"median":-10.957407,"eighty":-6.374465,"marketCap":1726699379},{"date":"2024-09-13","current":-6.904742,"twenty":-14.68632,"median":-10.606446,"eighty":-6.374465,"marketCap":1893128235},{"date":"2024-09-20","current":-7.430039,"twenty":-14.481851,"median":-10.304733,"eighty":-6.410301,"marketCap":2037153206},{"date":"2024-09-27","current":-7.634321,"twenty":-14.416972,"median":-9.973946,"eighty":-6.432454,"marketCap":2093162917},{"date":"2024-10-04","current":-7.905725,"twenty":-14.387481,"median":-9.835887,"eighty":-6.454177,"marketCap":2167575819},{"date":"2024-10-11","current":-8.988421,"twenty":-14.365855,"median":-9.536197,"eighty":-6.471402,"marketCap":2464427288},{"date":"2024-10-18","current":-9.898936,"twenty":-14.275648,"median":-9.492422,"eighty":-6.494727,"marketCap":2714070572},{"date":"2024-10-25","current":-7.587628,"twenty":-14.23812,"median":-9.435178,"eighty":-6.5109,"marketCap":2080360698},{"date":"2024-10-31","current":-7.126534,"twenty":-14.186945,"median":-9.414974,"eighty":-6.517189,"marketCap":1953938778},{"date":"2024-11-08","current":-7.599301,"twenty":-14.11026,"median":-9.329429,"eighty":-6.519524,"marketCap":2083561252},{"date":"2024-11-15","current":-6.430581,"twenty":-14.036864,"median":-9.246609,"eighty":-6.508113,"marketCap":1888648838},{"date":"2024-11-22","current":-5.330396,"twenty":-14.008036,"median":-9.078889,"eighty":-6.434404,"marketCap":1565526710},{"date":"2024-11-29","current":-5.467919,"twenty":-13.980511,"median":-8.972721,"eighty":-6.336098,"marketCap":1605916976},{"date":"2024-12-06","current":-5.313893,"twenty":-13.902792,"median":-8.614876,"eighty":-6.276185,"marketCap":1560679878},{"date":"2024-12-13","current":-5.819979,"twenty":-13.839429,"median":-8.495238,"eighty":-6.248553,"marketCap":1709316057},{"date":"2024-12-20","current":-5.775971,"twenty":-13.821153,"median":-8.377845,"eighty":-6.222869,"marketCap":1696391172},{"date":"2024-12-27","current":-6.238049,"twenty":-13.812967,"median":-8.200475,"eighty":-6.175381,"marketCap":1832102465},{"date":"2025-01-03","current":-1.083682,"twenty":-13.811432,"median":-8.147945,"eighty":-6.157876,"marketCap":318275296},{"date":"2025-01-10","current":-1.303719,"twenty":-13.766574,"median":-7.931581,"eighty":-6.140538,"marketCap":382899721},{"date":"2025-01-17","current":-1.193701,"twenty":-13.753032,"median":-7.891133,"eighty":-6.119668,"marketCap":350587508},{"date":"2025-01-24","current":-1.1882,"twenty":-13.716154,"median":-7.812392,"eighty":-6.085275,"marketCap":348971898},{"date":"2025-01-31","current":-1.056178,"twenty":-13.615504,"median":-7.634321,"eighty":-6.067691,"marketCap":310197242},{"date":"2025-02-07","current":-1.07268,"twenty":-13.546812,"median":-7.564281,"eighty":-5.978405,"marketCap":315044074},{"date":"2025-02-14","current":-0.929656,"twenty":-13.337262,"median":-7.53602,"eighty":-5.966304,"marketCap":273038198},{"date":"2025-02-21","current":-0.940658,"twenty":-13.1053,"median":-7.470895,"eighty":-5.920328,"marketCap":276269419},{"date":"2025-02-28","current":-0.852643,"twenty":-12.883791,"median":-7.424202,"eighty":-5.847483,"marketCap":250419649},{"date":"2025-03-07","current":-1.009931,"twenty":-12.773914,"median":-7.253346,"eighty":-5.800175,"marketCap":246207962},{"date":"2025-03-14","current":-0.930199,"twenty":-12.763183,"median":-7.144044,"eighty":-5.763741,"marketCap":226770492},{"date":"2025-03-21","current":-0.770737,"twenty":-12.752113,"median":-7.105005,"eighty":-5.687956,"marketCap":187895550},{"date":"2025-03-28","current":-0.730871,"twenty":-12.743752,"median":-7.036301,"eighty":-5.574632,"marketCap":178176815},{"date":"2025-04-04","current":-0.564099,"twenty":-12.730087,"median":-6.998128,"eighty":-5.417311,"marketCap":137520105},{"date":"2025-04-11","current":-0.476129,"twenty":-12.580434,"median":-6.945391,"eighty":-5.374404,"marketCap":116074096},{"date":"2025-04-17","current":-0.41859,"twenty":-12.352677,"median":-6.926527,"eighty":-5.321594,"marketCap":102046721},{"date":"2025-04-25","current":-0.497989,"twenty":-12.291873,"median":-6.904742,"eighty":-1.375231,"marketCap":121403202},{"date":"2025-05-02","current":-0.511809,"twenty":-12.245663,"median":-6.881395,"eighty":-1.223405,"marketCap":124772347},{"date":"2025-05-09","current":-0.423699,"twenty":-12.15573,"median":-6.846375,"eighty":-1.1893,"marketCap":103292222},{"date":"2025-05-16","current":-0.417316,"twenty":-12.148314,"median":-6.834702,"eighty":-1.12879,"marketCap":107691766},{"date":"2025-05-23","current":-0.449909,"twenty":-12.121955,"median":-6.75723,"eighty":-1.07488,"marketCap":116102658},{"date":"2025-05-30","current":-0.450473,"twenty":-12.120637,"median":-6.747152,"eighty":-1.061679,"marketCap":116248231},{"date":"2025-06-06","current":-0.507762,"twenty":-12.041995,"median":-6.685868,"eighty":-1.033834,"marketCap":131031991}],"updateTime":1749345909779}}}